



## DR. MARTENS AGREES DISTRIBUTION PARTNERSHIP FOR THE UAE, AND FURTHER EXPANSION INTO LATIN AMERICA

**2<sup>nd</sup> October 2025:** Dr. Martens, the iconic British footwear brand with a global presence, today announces a new distribution partnership agreement with Beside Group in the UAE, representing the brand's entry into the UAE for the first time. Additionally, the brand has partnered with Crosby in Latin America, which opened a store in Santiago, Chile this week - its second in the region following the opening of a store in Argentina in August.

These partnerships mark an important milestone in Dr. Martens' next phase of growth, as part of the strategic objective of curating market-right distribution and entering new growth markets with capital-light models.

Beside is a leading partner for international brands in the Middle East, with significant experience in retail and wholesale, spanning several decades. The partnership with Dr. Martens will launch and then grow the brand's presence in the UAE, initially through wholesale, with mono-branded store openings expected in the future.

Driven by a passion for design and quality, Crosby partners with iconic international fashion and luxury brands, serving as their official distributor in Latin America. The partnership with Dr. Martens will drive the brand's reach in Mexico, Argentina, Paraguay and Chile and includes mono-branded retail stores and wholesale. The first mono-branded Dr. Martens store opened in Palermo, Buenos Aires, in August, to great reception. A second store, in Santiago, opened this week, marking the brand's first store in Chile.

**Ije Nwokorie, CEO of Dr. Martens, said:** *"These exciting partnerships are consistent with our strategy of entering new growth markets to reach more consumers than ever before through a capital-light approach. We see enormous potential for Dr. Martens in the UAE and Latin America and are delighted to have two partners who really understand both the depth and breadth of our iconic brand."*

**Ends**

### **Investors and analysts:**

Bethany Barnes, Director of Investor Relations & Corporate Communications  
[bethany.barnes@drmartens.com](mailto:bethany.barnes@drmartens.com)  
+44782187465

### **Press enquiries:**

Rob Greening / Ludo Baynham-Herd  
[drmartens@client.sodali.com](mailto:drmartens@client.sodali.com)  
+44 207 250 1446

### **Notes to editors**

#### **About Dr. Martens**

Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England. Its first silhouette, the 1460 boot - named after the date it was produced - rolled off the production line on 1st April 1960. Originally chosen by workers for their air-cushioned comfort and durability, "Docs" or "DM's" were later adopted by musicians and subcultural pioneers who took them from the street to the global stage.

Over six decades later, Dr. Martens operates in more than 60 countries and employs around 3,700 people. The company continues to honour the brand's heritage through its 'Made in England' footwear, manufactured at its original Northamptonshire factory, while meeting global demand from multiple high-quality production sites across Asia. All our products are made with an unwavering commitment to craft, combined with innovative techniques.

Dr. Martens business spans Direct-to-Consumer (Retail and Ecommerce) and Wholesale channels, with product segments including the brand's Original silhouette (the 1460 boot, 1461 shoe, 2876

with product segments including the brand's Original silhouettes (the 1460 boot, 1461 shoe, 2970 Chelsea boot, and Adrian loafer), Sandals, new product families such as Zebzag and Buzz, a Kids range, and an expanding line of bags and accessories. Each collection embodies durability, versatility, and individuality, while collaborations continue to push creative boundaries and reach new wearers. Dr. Martens has transcended its roots while staying true to its DNA - and the brand's trademark yellow welt stitching, grooved sole edge, and scripted "With Bouncing Soles" heel loops are instantly recognisable worldwide.

Dr. Martens plc (DOCS.L) is listed on the main market of the London Stock Exchange and is a constituent of the FTSE 250 index.

For more information, visit [www.drmartens.com](http://www.drmartens.com) or [www.drmartensplc.com](http://www.drmartensplc.com)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lseg.com](mailto:ms@lseg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAFSDFIFEISEES